Drug-Induced QT Prolongation: Cardiac Safety Assessment in Clinical Development and Pharmacovigilance

Drug-induced QT prolongation is an important cardiac-safety concern because delayed ventricular repolarisation can increase susceptibility to torsade de pointes and other malignant ventricular arrhythmias. The crucial distinction is that QTc prolongation is a biomarker of repolarisation delay, not a direct measurement of an individual's torsade risk.

Regulatory and Scientific Framework

ICH E14 addresses clinical evaluation of QT/QTc prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH S7B addresses nonclinical evaluation of delayed ventricular repolarisation. Their integrated Questions and Answers were adopted at Step 4 on 21 February 2022 and explain how clinical and nonclinical evidence can be considered together.

This framework does not reduce cardiac safety to a single cutoff. Interpretation may include:

• quality and reproducibility of ECG data;
• magnitude and timing of QTc change;
• heart-rate effects;
• concentration-QTc relationships;
• nonclinical ion-channel and in-vivo findings;
• exposure margins;
• ventricular arrhythmias or syncope;
• electrolyte abnormalities;
• interacting medicines; and
• patient susceptibility factors.

Understanding QT and QTc

The QT interval extends from ventricular depolarisation to completion of ventricular repolarisation on the surface ECG. Because QT duration varies with heart rate, corrected values—QTc—are used for comparison.

Common correction methods include Fridericia and Bazett formulas, although the scientifically appropriate correction depends on the dataset and heart-rate range. Correction choice should be prespecified or otherwise justified rather than selected to obtain a preferred result.

Why QT Prolongation Matters

Delayed repolarisation can facilitate early afterdepolarisations and increase susceptibility to torsade de pointes. Inhibition of the rapid delayed rectifier potassium current, often associated with hERG channel effects, is a common mechanism, but proarrhythmic liability reflects the integrated effect of multiple ion channels, exposure and patient factors.

Not every medicine that prolongs QTc causes torsade, and absence of a marked mean QTc effect does not make every individual arrhythmic event irrelevant.

Major Susceptibility Factors

Risk can be modified by:

• congenital long-QT syndromes;
• bradycardia;
• hypokalaemia, hypomagnesaemia or hypocalcaemia;
• structural heart disease;
• female sex and older age in some contexts;
• renal or hepatic impairment affecting exposure;
• high drug concentrations;
• interacting medicines; and
• concomitant QT-prolonging drugs.

These factors should modify interpretation rather than function as automatic proof or exclusion of causality.

Individual ECG Assessment

A potentially important QT finding should first be verified. The reviewer should establish ECG timing, dose and concentration context, heart rate, raw QT, correction method, QRS duration, baseline value and repeat measurements where available.

An isolated automated value can be misleading. Clinically important findings may require central or expert measurement, repeat ECGs or review of the underlying waveform.

Concentration-QTc and Population-Level Assessment

Modern QT assessment often examines the relationship between drug concentration and QTc change rather than relying only on categorical threshold counts. The objective is to understand whether repolarisation effects increase with exposure and whether the observed effect is clinically relevant across the expected concentration range.

The model should be interpreted together with ECG quality, study design, heart-rate effects, active controls or assay-sensitivity evidence where applicable, and the extent to which the observed exposure range covers clinically plausible high concentrations.

Nonclinical Integration Under S7B

Nonclinical evidence can include effects on relevant cardiac ion currents, especially hERG/IKr, and in-vivo QT or repolarisation findings. The E14/S7B Q&As support an integrated approach in which high-quality nonclinical evidence can materially inform clinical interpretation.

A single hERG result should not be treated as the entire proarrhythmia assessment. Assay quality, exposure margins, multi-ion-channel effects, in-vivo findings and the totality of evidence matter.

QTc Versus Torsade de Pointes

Torsade de pointes is a clinical ventricular arrhythmia. QTc prolongation is a risk biomarker. The relationship is probabilistic rather than deterministic.

A patient with marked QTc prolongation and several susceptibility factors may warrant urgent clinical action even without documented torsade. Conversely, a modest mean QTc effect in a trial does not automatically translate into a clinically meaningful torsade risk.

Clinical-Development Interpretation

A development programme should integrate:

• central tendency and outlier analyses;
• concentration-QTc results;
• treatment-emergent arrhythmias, syncope or sudden death;
• ECG morphology and conduction changes;
• nonclinical findings;
• dose and exposure margins;
• effects of renal/hepatic impairment and interactions; and
• high-risk subgroups.

The conclusions should be proportionate to the evidence. A measurable QTc effect may justify exposure limits, interaction controls, monitoring or labelling without implying that torsade has been observed.

Post-Marketing Pharmacovigilance

Spontaneous reports of long QT, torsade, ventricular tachycardia, syncope or sudden death should be followed for ECG evidence, correction method, timing, electrolytes, concomitant medicines, interacting factors, organ impairment and outcome.

Signal assessment should distinguish:

• isolated QTc prolongation;
• documented torsade de pointes;
• other ventricular arrhythmias;
• syncope without rhythm documentation; and
• sudden death with limited diagnostic information.

These events may contribute differently to the product-level proarrhythmia assessment.

Drug Interactions and Exposure

A product may have limited QT effect at usual exposure but greater risk when concentrations rise because of metabolic inhibition, renal/hepatic impairment, overdose or interacting medicines. Exposure-based reasoning is therefore central to both development and post-marketing assessment.

Practical Medical Review Sequence

1. Confirm the ECG finding and measurement quality.
2. Establish baseline QTc and relevant cardiovascular history.
3. Reconstruct timing relative to dose and exposure.
4. Review heart rate, QRS duration and correction method.
5. Assess electrolytes, organ impairment, interacting medicines and other susceptibility factors.
6. Determine whether arrhythmia, syncope or other clinical outcomes occurred.
7. Integrate concentration-QTc and nonclinical S7B evidence where relevant.
8. State the product-level proarrhythmia conclusion with appropriate uncertainty.

Potential Failure Modes

The following are illustrative failure modes, not reported inspection findings.

Governance and Inspection Considerations

For a material QT/proarrhythmia concern, assessors may examine ECG data quality, predefined analysis methods, exposure-response reasoning, handling of outliers, integration of nonclinical evidence and follow-up of serious arrhythmic events. No universal internal QT committee or fixed monitoring schedule applies to every product; controls should follow the development programme and established risk.

Practical Review Checklist

1. Is the QT/QTc measurement reliable?
2. Is the correction method appropriate and consistent?
3. Are baseline and treatment-emergent changes distinguished?
4. Is exposure-response information considered?
5. Are electrolytes, organ function and interactions assessed?
6. Are clinical arrhythmias distinguished from QT biomarkers?
7. Is nonclinical S7B evidence integrated proportionately?
8. Does the conclusion describe proarrhythmic risk rather than merely list QT values?

Relationship With Other QPPV.com Articles

For the broader cardiovascular framework see [[drug-induced-cardiac-toxicity-pharmacovigilance]]. This article also complements [[signal-assessment]] and [[causality-assessment-in-pharmacovigilance]].

Key Takeaways

QTc prolongation is a biomarker of delayed ventricular repolarisation, not a direct measurement of torsade risk.

Modern assessment integrates ECG quality, magnitude of effect, exposure-response, nonclinical evidence, clinical arrhythmias and patient susceptibility.

ICH E14 and S7B form a specialised regulatory framework for proarrhythmic potential and should be applied as an integrated evidence model rather than as isolated threshold rules.

References

1. International Council for Harmonisation. ICH E14: Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs.
2. International Council for Harmonisation. ICH S7B: Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization by Human Pharmaceuticals.
3. International Council for Harmonisation. ICH E14/S7B Questions and Answers. Step 4, adopted 21 February 2022.
4. International Council for Harmonisation. ICH S7A: Safety Pharmacology Studies for Human Pharmaceuticals.
5. European Medicines Agency. GVP Module IX — Signal management (Rev. 1), with current EMA implementation material.

Regulatory Note

The ICH E14/S7B integrated Questions and Answers were adopted at Step 4 on 21 February 2022. The framework supports integrated clinical and nonclinical assessment of QT/QTc prolongation and proarrhythmic potential; it does not make a single QTc threshold, hERG result or isolated event an automatic determination of clinical torsade risk or drug causality.